anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive TOFA at study entry (week 0) as treatment for UC according to standard clinical practice and recommended dosage of the drug, and will be followed up to 52 weeks. At baseline, all enrolled patients will undergo a detailed assessment including gender, age, duration of disease, smoking status, extension of disease (according to Montreal classification), clinical activity (assessed with the partial Mayo Score), C-Reactive Protein (CRP) values, faecal calprotectin, previous and concomitant therapies, data on SpA (axial vs. peripheral SpA, and assessment of ASDAS-CRP and/or DAS28-CRP scores). The joint response (JR), steroid free joint response (SFJR), clinical intestinal response (CIR), steroid free clinical intestinal remission (SFCIR), CRP and calprotectin values will be assessed at 8, 24 and 52 weeks (see further for the definitions of the outcomes). The burden of UC and therapy with TOFA on work productivity and health- related quality of life will be evaluated through the administration of the Work Productivity and Activity Impairment (WPAI) Questionnaire and the Short Inflammatory Bowel Disease Questionnaire Score (Short IBDQ), respectively, at baseline and at 24 and 52 weeks. The patients will be assessed with direct visits and biochemical evaluations, including monitoring of serum lipid levels, according to the routine clinical practice established for subjects treated with TOFA. The support by a rheumatologist is suggested in the clinical evaluation of patients All data will be collected anonymously in a specifically arranged eCRF form inside the IG-IBD registry.
Mite extract is a sterile solution containing the extractables of mite whole bodies in 0.25% sodium chloride, 0.125% sodium bicarbonate, 50% glycerol by volume and 0.4% phenol as a preservative. The mites are grown on a medium of yeast and pork and are handled and cleaned in a manner to remove more than 99% of the food medium. The medium contains no material of human origin.

This extract may be administered by the scratch, prick-puncture, or intradermal methods of skin testing for diagnostic purposes and subcutaneously for therapeutic purposes as directed under Dosage and Administration.

Intradermal skin tests in patients who were puncture test positive (Sum E ≥ 40 mm) to either D. farinae or D. pteronyssinus extract were performed with extracts of the mite food medium obtained from the same supplier. The results, submitted to the FDA by several manufacturers, were as follows: By intradermal testing, there was 1 positive (Sum E ≥ 20 mm) in 44 individuals at an estimated 1% level of medium content (approximately the same as contained in the mite extract). At a ten-fold increase (estimated 10% medium content), 4 positives in 40 individuals were observed. Two of the individuals who were skin test positive to the mite extract and who also were skin test positive to the medium extract were also skin test positive to an extract of yeast ( Saccharomyces sp.) when tested by the puncture method. 

The extract is standardized by comparing its relative potency by ELISA competition to a U.S. reference mite extract available from the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. The U.S. reference extract has been assigned a potency of 10,000 AU/mL based on quantitative skin testing 1.
Mesothelioma is a cancer that is caused by exposure to asbestos, an environmental contaminant. This cancer is incurable and lacks effective treatment, particularly after initial chemotherapy. There has not been a licenced therapy for mesothelioma since 2003, and no treatment has yet demonstrated an improvement in survival following initial chemotherapy. There is an urgent need to explore more effective approaches to therapy. Targeted treatments offer potential hope for the treatment of mesothelioma. A class of drugs called PARP (Poly Adenosine Diphosphate-ribose polymerase) inhibitors have already been proven to improve the survival of patients with breast and ovarian cancers, that carry specific mutations. Mesothelioma has been shown in a recent trial to respond to this class of agent. Further investigation is warranted to test whether PARP inhibitors could be a new treatment option for patients. As with ovarian cancer studies of the past, the NERO trial will test a PARP inhibitor (niraparib) after successful treatment with chemotherapy. Patients whose tumours shrink or stabilise following chemotherapy are expected to have a greater chance of benefit from niraparib. It's not known if niraparib will be able to improve survival of patients with mesothelioma, or indeed whether or not toxicity could occur without benefit. For that reason, patients will be randomised with a 2:1 chance of receiving the drug. Those patients who do not receive niraparib will be closely monitored for signs of early tumour growth so that they can go on to receive an alternative treatment if necessary. If the NERO trial is positive, this study will lead to the approval of a new medicine for use around the world, one that would extend the life expectancy of patients for the first time following initial chemotherapy. NERO will recruit 84 patients over 12 months. Those randomised to receive niraparib will receive a daily dose of 200 mg or 300mg for up to 24 weeks within the trial.
PURPOSE:To provide an antirheumatic agent containing a 2-acylthio-methyl-3- benzyolpropionic acid derivative as an active component, having weak side effect and toxicity and excellent immuno-regulation function and effective for the remedy of immuno-insufficiency diseases. CONSTITUTION:A benzoylpropionic acid derivative of formula I (R<1> is H, lower alkyl, etc.; R<2> is lower alkyl or phenyl; X is H, halogen, etc.; Y is H or lower alkyl) is used as an antirheumatic agent. The compound of formula I strongly suppresses adjuvant arthritis and has immuno-regulating activity and antiarthritis activity. The compound of formula I is useful also as a remedy for immuno- insufficiency diseases such as arthrorheumatism, autoimmune diseases, various carcinomas, bacteriosis, asthma, hepatopathy, etc., and has low side effect and toxicity. The compound can be produced by reacting the compound of formula II with the compound of formula R<2>COSH in an organic solvent in the presence of a basic catalyst.
Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
The present invention relates to a female external use cleaning and health care ball, which is composed of a body, a net encapsulating body and an operating wire. The body is roughly a ball shape, and is composed of borneol, dragon blood, centipede, sophora flavescens, bombyx batryticatus, common cnidium fruit. The net encapsulating body has an opening, and may encapsulate the exterior of the body after the body is placed therein. The net encapsulating body is composed of sterilized gauze, and the opening is closed by means of the operating wire. One end of the operating wire is used as the opening of the net encapsulating body, and the other end is used to move the body of the present invention. When in use, the body is placed deep in the vagina, and the outer end of the operating wire is located at the vagina entrance. After the placement for a suitable period of time, the body may be extracted by pulling the operating wire. The present invention is suitable for cleaning the interior of vagina as an ideal health care product.
INTRODUCTION: Postpartum haemorrhage (PPH) remains the leading cause of maternal death. Yet there is a lack of clarity around what research is needed to determine what works and how best to deliver proven PPH interventions. This article describes a WHO-led effort to develop a global PPH research agenda for 2023-2030, to reinvigorate research and innovation while avoiding duplication and waste.
METHODS: Potential questions were culled from evidence gaps in a forthcoming Lancet PPH series, a pipeline analysis on PPH medicines and devices, international PPH guidelines, previous research prioritisation efforts and submissions from a reference group of PPH experts and stakeholders. Questions were deduplicated and consolidated, categorised into three tracks (innovation, implementation and cross-cutting) and subjected to an online prioritisation survey. Survey participants (n=120) assessed these questions using five criteria (answerability, effectiveness, deliverability, maximum potential for disease burden reduction and equity) following the Child Health and Nutrition Research Initiative methodology. The outcome of this exercise was complemented by an in-person consensus meeting (Global PPH Summit from 7 March 2023 to 10 March 2023 in Dubai, United Arab Emirates) to finalise the research agenda.
RESULTS: Fifteen research questions (five per track) were identified as top priority. The top question per track called for research on the comparative effectiveness and safety of alternative routes of administration (other than the intravenous route) of tranexamic acid in the treatment of PPH (innovation); identifying barriers and facilitators affecting the adoption and use of evidence-based recommendations for PPH management (implementation) and the effectiveness of a strategy of early detection and first response treatment using a bundle of recommended interventions for improving PPH-related outcomes (cross-cutting).
CONCLUSION: This shared research agenda should guide future investments into PPH studies with high potential to transform policy and clinical practice in the near term to medium term. Funding for the new research priorities is urgently needed.
A moxifloxacin hydrochloride ophthalmic gel relates to the field of pharmaceutical preparations, and adopts a guar gum/polyvinyl alcohol composite gel system. The guar gum has good water solubility, shows high viscosity under low mass fraction, can prolong the contact time of the medicine and eyeball cells, and realizes the effect of prolonging the medicine effect. The polyvinyl alcohol has good biocompatibility, not only improves the stability of the system, but also has the effect similar to that of artificial tears, and reduces the stimulation of the medicine to eyes. The moxifloxacin hydrochloride ophthalmic gel has the advantages of wide antibacterial spectrum, good stability, lasting curative effect and good biological adhesion to eyes. In addition, the eye cream does not contain preservatives, has less irritation to eyes and is safer to use. The preparation method of the moxifloxacin hydrochloride ophthalmic gel is simple to operate, has low requirements on equipment, and can realize industrial large-scale production.
Hepatic enzyme elevations have been observed in patients treated with VOYDEYA [see Adverse Reactions (6.1)]. Fourteen percent of patients receiving VOYDEYA in Study ALXN2040-PNH-301 had elevations in serum alanine aminotransferase (ALT). ALT elevations > 3 × the upper limit of normal (ULN) and ≤ 5 × ULN occurred in 9% of VOYDEYA-treated patients, and ALT elevations > 5 × ULN and ≤ 10 × ULN occurred in 5% of VOYDEYA-treated patients.

Assess liver enzyme test results prior to the initiation of VOYDEYA and periodically during treatment. Consider treatment interruption or discontinuation if elevations are clinically significant or if the patient becomes symptomatic. VOYDEYA has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.7)].
The invention discloses a medicine composition containing oxiracetam and aceglutamide. The medicine composition is prepared from the following components in parts by weight: 300-500 parts of oxiracetam, 50-150 parts of aceglutamide and 100-300 parts of glucose. The invention further discloses a preparation method of the medicine composition containing the oxiracetam and the aceglutamide. The invention further discloses application of the medicine composition. The medicine composition can be selectively used for cerebral cortexes to simulate hippocampus tissue neural pathways, so as to activate, protect and repair cerebral nerve cells; the medicine composition is mainly used for treating various types of cerebral injuries, such as dementia, cerebrovascular diseases and postoperative recovery of various types of brain surgeries. With the adoption of the medicine, the revival of unconscious patients after neurosurgery operations can be promoted, and the hypomnesis of middle-aged and old people is improved.
Children in this group received a red-light apparatus (LS-03B; Yishiliang Inc), which has been deemed safe by the State Administration for Market Regulation of China. They were directed to utilize this apparatus twice a day for 3-minute sessions, ensuring a gap of over 4 hours between each use.
Anti-idiotypic antibodies that mimic tumor necrosis factor (TNF) activity. The antibodies may be raised in one species (e.g. a rabbit) using a monoclonal anti-TNF antibody from another species (e.g. a mouse) as an immunogen. Such anti-idiotypic antibodies were cytotoxic to TNF-sensitive cell lines. The cytotoxic activity of the anti-idiotypic antibodies can be neutralized by antibodies that bind to TNF. The anti-idiotypic antibodies may be useful themselves as TNT antagonists or as TNF agonists, and may also be the basis for a new group of TNF agonists or antagonists.
<P>PROBLEM TO BE SOLVED: To allow a doctor to efficiently collect medicine-related article information from a large number of medicine-related article makers by one question.  <P>SOLUTION: A doctor side personal computer 1, a plurality of maker side personal computers 2 and a server 3 are communicably connected via a network. When the doctor asks one question from the doctor side personal computer 1, the server 3 creates a question list on the basis of question information, and performs provision for browsing each of the unspecified large number of maker side personal computers 2. When each the maker browsing the question list selects one or a plurality pieces of question information and performs an answer, the medicine-related article information of the answer is transmitted to the doctor side personal computer 1 from each the maker side personal computer 2 through the sever 3. Thereby, the doctor can efficiently collect the medicine-related article information from the large number of medicine-related article makers by one question.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Precise nerve detection during surgery is crucial for safe operational outcomes, which largely depend on the surgeon's skills. Therefore, automatic real-time identification of anatomical structures is of great importance. However, image processing times must be kept as low as possible to be a viable solution for real-time visual identification. By using a general purpose graphics processing unit (GPGPU) implementation for birefringence mapping, the process can achieve rates of 43 frames per second (FPS); a 118x gain from a CPU implementation. Furthermore, by including a deep learning network, the complete framework can automatically detect nerves close to 12 FPS. By leveraging GPU for the processing task, the framework can run on compact devices with NVIDIA modules, such as Jetson Xavier AGX, while still achieving reasonably fast nerve identification and visualization.
BACKGROUND: Patients living with and beyond breast cancer frequently exhibit several side effects that can impact quality of life and physical functioning way beyond diagnosis and cancer therapies. Traditional on-land exercise has shown to be effective in reducing several symptoms of BC but little is known about the role of water-based exercise in improving physical and psychological well-being.
OBJECTIVES: To compare land- vs. water-based exercise training for BC survivors to improve Health-Related Quality of Life (HRQoL), cancer-related fatigue (CRF), physical functioning, body composition and physical activity in patients with BC.
METHODS: A randomised, parallel group (1:1) controlled trial was conducted between 2020 and 2022. Patients were randomly allocated to complete a similar exercise training twice weekly during 12 weeks either on land (LG) using traditional gym equipment or in a swimming pool (WG) using body-weight exercises and water-suitable accessories. Both groups were supervised and monitored by an experienced physiotherapist. Main outcome was HRQoL (EORTC QLQ C30 and B23 module) and CRF measured with the Piper Scale. Secondary variables included functional capacity with the 6 Minutes Walking Test (6MWT), upper and lower body strength (handgrip strength and 30″ Sit-to-Stand (STS) test), body composition and objectively measured physical activity.
RESULTS: 28 patients were assessed and randomised during the study period. One patient did not receive the allocated intervention due to skin issues and one patient was dropped out during the intervention. A significant effect of time was found for both symptom severity (F(2,52) = 6.46, p = 0.003) and overall functioning (F1.67,43.45 = 5.215, p =0 .013) but no interaction was found between group and time. No effects were reported for CRF. Similar findings were reported for functional capacity (time effect F1.231,32.019 = 16.818, p < 0.001) and lower body strength (time effect F2,52 = 15.120, p < 0.001) as well as fat mass (time effect F2,52 = 4.38, p = 0.017). Notably, a significant time per group interaction was reported for physical activity (F2,52 = 6.349, p =0.003) with patients in the WG significantly improving PA levels over time while patients in the LG exhibited a marked decreased.
CONCLUSIONS: Exercise training either in water or on land can decrease symptom severity and improve functionality and body composition. Water-based training seems more effecting than land-based exercise to improve physical activity patterns over time.
The two nucleoredoxin genes, NXNL1 and NXNL2 encode by alternative splicing for a secreted truncated thioredoxin that mediates neuronal survival and a thioredoxin enzyme that regulates the phosphorylation of TAU. Behavioral analyses of young Nxnl2 -/- mice demonstrate that this gene is involved in regulating of brain functions and is essential for learning and memory exerting positive effects on long-term potentiation (LTP) in the hippocampus. LTP dysfunction on the young Nxnl2 -/- mice can be fully corrected by the synergistic action of the two products of the Nxnl2 gene. Aging Nxnl2 -/- mice have brain stigmata of tauopathy as seen by oligomerization, phosphorylation and aggregation of TAU. This late occurring tauopathy can be prevented, by recombinant AAVs encoding RdCVF2 and RdCVF2L when administrated to young animals, which is of significant interest for therapeutic perspectives. Therefore, the present invention relates to a method of treating a tauopathy in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a first polynucleotide encoding for the short isoform of the NXNL2 gene, Rod-derived Cone Viability Factor (RdCVF2) and of a second polynucleotide encoding the long isoform of the NXNL2 gene, RdCVF2L.
INTRODUCTION: Exploring the energy expenditure and substrate metabolism data during exercise, 10-minute recovery, and 20-minute recovery phases in Tabata, HIIT(High-Intensity Interval Training), and MICT(Moderate-Intensity Continuous Training). This study explores the scientific aspects of weight reduction strategies, examining energy expenditure and substrate metabolism from various training perspectives. The aim is to establish a theoretical foundation for tailoring targeted exercise plans for individuals within the population with overweight/obesity.
METHODS: This study used an experimental design with fifteen male university students with overweight/obesity. Participants underwent random testing with Tabata, HIIT, and MICT. Tabata involved eight sets of 20 seconds exercise and 10 seconds rest, totaling 4 minutes. HIIT included four sets of power cycling: 3 minutes at 80% VO2max intensity followed by 2 minutes at 20% VO2max. MICT comprised 30 minutes of exercise at 50% VO2max intensity. Gas metabolism indices were continuously measured. Subsequently, fat and glucose oxidation rates, along with energy expenditure, were calculated for each exercise type.
RESULTS: During both the exercise and recovery phases, the Tabata group exhibited a significantly higher fat oxidation rate of (0.27 ± 0.03 g/min) compared to the HIIT group (0.20 ± 0.04 g/min, p<0.05) and the MICT group (0.20 ± 0.03g/min, p<0.001). No significant difference was observed between the HIIT and MICT groups (p=0.854). In terms of energy expenditure rate, the Tabata group maintained a substantially elevated level at 5.76 ± 0.74kcal/min compared to the HIIT group (4.81 ± 0.25kcal/min, p<0.01) and the MICT group (3.45 ± 0.25kcal/min, p<0.001). Additionally, the energy expenditure rate of the HIIT group surpassed that of the MICT group significantly (p<0.001).
CONCLUSION: The study finds that male college students with overweight/obesity in both exercise and recovery, Tabata group has lower fat and glucose oxidation rates, and energy expenditure compared to HIIT and MICT groups. However, over the entire process, Tabata still exhibits significantly higher rates in these aspects than HIIT and MICT. Despite a shorter exercise duration, Tabata shows a noticeable "time-efficiency" advantage. Tabata can be used as an efficient short-term weight loss exercise program for male college students with overweight/obesity.
The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF.alpha., comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF.alpha., wherein the encoded domain or subdomain replaces a cleavage site of native TNF.alpha., and a second nucleotide sequence encoding a domain or subdomain of native TNF.alpha. that binds to a TNF.alpha. receptor. The encoded chimeric TNF.alpha. is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF.alpha. receptor on the surface of a cell.  The chimeric TNF.alpha. is therefore useful in methods for inducing apoptosis of a cell expressing a TNF.alpha. receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF.alpha.  that is expressed on the surface of the cell.